U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C14H23NO.2C4H4O4.H2O
Molecular Weight 692.8366
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of TAPENTADOL MALEATE HEMIHYDRATE

SMILES

O.OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CC[C@H]([C@@H](C)CN(C)C)C1=CC=CC(O)=C1.CC[C@H]([C@@H](C)CN(C)C)C2=CC=CC(O)=C2

InChI

InChIKey=ZDYFCLLYJFXWDY-ALHIZKRASA-N
InChI=1S/2C14H23NO.2C4H4O4.H2O/c2*1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12;2*5-3(6)1-2-4(7)8;/h2*6-9,11,14,16H,5,10H2,1-4H3;2*1-2H,(H,5,6)(H,7,8);1H2/b;;2*2-1-;/t2*11-,14+;;;/m00.../s1

HIDE SMILES / InChI

Description

Tapentadol is the first US FDA-approved centrally acting analgesic having both μ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition. Tapentadol is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.16 µM [Ki]
8.8 µM [Ki]
5.28 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NUCYNTA

Cmax

ValueDoseCo-administeredAnalytePopulation
221.34 ng/mL
86 mg single, oral
TAPENTADOL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
221.34 ng × h/mL
86 mg single, oral
TAPENTADOL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
1.16 h
86 mg single, oral
TAPENTADOL plasma
Homo sapiens
4 h
100 mg single, oral
TAPENTADOL plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
100 mg single, oral
TAPENTADOL plasma
Homo sapiens

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
As with many centrally-acting analgesic medications, the dosing regimen of NUCYNTA® should be individualized according to the severity of pain being treated, the previous experience with similar drugs and the ability to monitor the patient. Initiate NUCYNTA® with or without food at a dose of 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability. Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are, therefore, not recommended.
Route of Administration: Oral
In Vitro Use Guide
Upon exposure to tramadol and tapentadol concentrations up to 600μM, cell toxicity was assessed through evaluation of oxidative stress, mitochondrial and metabolic alterations, as well as cell viability and death mechanisms through necrosis or apoptosis, and related signalling. Tapentadol was observed to trigger much more prominent toxic effects than tramadol, ultimately leading to energy deficit and cell death.